9:00am - 5:00pm

Office Hours Mon. - Fri.

800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Archive

Ganetespib With Platinum, in Patients With Malignant Pleural Mesothelioma

ConditionLung Cancer - Malignant Pleural MesotheliomaEstimated Enrollment: 27Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: UCL/12/0158|CMS # 1995|A15183|2012-001598-10|TBCStudy First Received: April 30, 2012Last Updated: October 26, 2016Estimated Primary Completion Date: September 2017Primary Outcome Measures:Maximum Tolerated Dose of Ganetespib|Progression Free SurvivalSponsors and Collaborators:University College, London|Cancer Research UKResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT01590160...

Continue reading

Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma

ConditionLung Cancer|MesotheliomaEstimated Enrollment: 28Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: TreatmentStudy ID Numbers: 2014-0497|NCI-2014-02568Study First Received: November 11, 2014Last Updated: February 15, 2017Estimated Primary Completion Date: May 2021Primary Outcome Measures:Disease Control Rate (DCR)|Response RateSponsors and Collaborators:M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc.Result Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT02293005...

Continue reading

SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma

ConditionMesothelioma|Adenocarcinoma of Lung|Pancreatic NeoplasmsEstimated Enrollment: 55Age Group: 18 Years to 99 Years   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Primary Purpose: TreatmentStudy ID Numbers: 110160|11-C-0160Study First Received: May 27, 2011Last Updated: April 20, 2017Estimated Primary Completion Date: August 3, 2016Primary Outcome Measures:Objective response rate stratified by tumor type|SS1P antibody formation|Grade and description of adverse events|determine RP2D in drug lot FIL129J01|Overall survival|Progression-free survival|Duration of responseSponsors and Collaborators:National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)Result Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT01362790...

Continue reading

Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM).

ConditionMesothelioma, MalignantEstimated Enrollment: 108Age Group: 18 Years to 99 Years   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: TreatmentStudy ID Numbers: MORAb-009-201Study First Received: January 14, 2015Last Updated: February 8, 2017Estimated Primary Completion Date: September 2017Primary Outcome Measures:Overall Survival (OS)|Progression Free Survival (PFS)|Objective Response Rate [ORR]|Duration of response (DR)|Disease control rates (DCR)|Duration of disease control (DDC)|Health related quality of life (QOL)|Duration of Performance Status Maintenance (DPSM)|Safety and tolerability as a measure of number of participants with Adverse Events (AEs)/Serious Adverse Events (SAEs)|Pharmacokinetic (PK) and pharmacodynamic (PD) profileSponsors and Collaborators:MorphotekResult Received: No Study Results PostedWebsite...

Continue reading

Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma

ConditionMalignant Peritoneal MesotheliomaEstimated Enrollment: 35Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: 12-0032|NCI-2012-00332Study First Received: May 3, 2012Last Updated: June 24, 2016Estimated Primary Completion Date: June 2017Primary Outcome Measures:Objective response rate according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1|PFS|OS|Toxicity in terms of adverse events per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) criteria version 4.0|Disease control rate - SD + PR + CR|Percentage of patients who have activating EGFR mutations among all screened patientsSponsors and Collaborators:University of...

Continue reading

Combination Gene Transfer and Chemotherapy

ConditionMesotheliomaEstimated Enrollment: 40Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: UPCC 02510; 811318Study First Received: May 6, 2010Last Updated: October 10, 2016Estimated Primary Completion Date: October 2013Primary Outcome Measures:To determine the safety of administering intrapleural SCH 721015, Ad.hIFN-alpha2b (Adenoviral-mediated Interferon-alpha) in combination with chemotherapy for the management of MPM.|To estimate objective response rates and distribution|Time to ProgressionSponsors and Collaborators:Abramson Cancer Center of the University of PennsylvaniaResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT01119664...

Continue reading

Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma

ConditionMalignant Pleural MesotheliomaEstimated Enrollment: 60Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: TreatmentStudy ID Numbers: ADU-CL-02Study First Received: August 23, 2012Last Updated: January 25, 2017Estimated Primary Completion Date: June 2017Primary Outcome Measures:Number of subjects reporting adverse events|Induction of immune response to mesothelin by enzyme-linked immunosorbent spot (ELISPOT) assay|Objective tumor response|Time to progression|Serum mesothelin as correlate of therapeutic responseSponsors and Collaborators:Aduro Biotech, Inc.Result Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT01675765...

Continue reading

Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma (STELLAR)

ConditionMalignant Pleural MesotheliomaEstimated Enrollment: 80Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: TreatmentStudy ID Numbers: EF-23Study First Received: March 19, 2015Last Updated: March 28, 2017Estimated Primary Completion Date: February 2018Primary Outcome Measures:Overall Survival|Progression Free Survival|Response Rate|ToxicitySponsors and Collaborators:NovoCure Ltd.Result Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT02397928...

Continue reading

Dasatinib in Resectable Malignant Pleural Mesothelioma

ConditionMalignant Pleural MesotheliomaEstimated Enrollment: 60Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: 2006-0935|NCI-2010-01505|W81XWH-07-1-0306Study First Received: March 27, 2008Last Updated: September 23, 2016Estimated Primary Completion Date: March 2018Primary Outcome Measures:Modulation of biomarker p-Src Tyr419 expression|Progression-free SurvivalSponsors and Collaborators:M.D. Anderson Cancer Center|Bristol-Myers Squibb|United States Department of DefenseResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00652574...

Continue reading

Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy

ConditionMalignant MesotheliomaEstimated Enrollment: 68Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: TreatmentStudy ID Numbers: CALGB-30901|U10CA180821|U10CA031946|CDR0000667496Study First Received: March 11, 2010Last Updated: March 6, 2017Estimated Primary Completion Date: July 2017Primary Outcome Measures:Progression-free survival|Overall survival|Frequency of responses|ToxicitySponsors and Collaborators:Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)Result Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT01085630...

Continue reading